Poor Pharma

EU retaliation against Trump drug tariffs would be bad idea, says industry | Pharmaceuticals industry | The Guardian

Oelrich said data showed that a quarter of drugs in the past 10 years approved by FDA in the US had not made it to Europe because of non-tariff barriers, such as differing national regulations and pricing. “Many of the biotech companies are not even bothering engaging in Europe. For them it makes no sense,” he said.

Amazing: deciding how much you are willing to pay for a drug is viewed as a non-tariff barrier. It’s called the market.